Current Report Filing (8-k)
December 23 2020 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
December 21, 2020
SELLAS
Life Sciences Group, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-33958
|
|
20-8099512
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
7 Times Square, Suite 2503
New York, NY 10036
|
|
|
|
|
(Address of Principal Executive
Offices) (Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (646) 200-5278
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value per share
|
SLS
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
On December 21, 2020, SELLAS Life Sciences Group, Inc.
(the “Company”) issued a press release announcing favorable initial data from two clinical studies of galinpepimut-S,
the Company’s Wilms Tumor-1-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies in patients
with two different types of advanced solid cancers who had exhausted standard therapy options.
A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SELLAS Life Sciences Group, Inc.
|
|
|
|
|
Date:
|
December 23, 2020
|
By:
|
|
/s/ Barbara A. Wood
|
|
|
|
Name:
|
Barbara A. Wood
|
|
|
|
Title:
|
Executive Vice President, General Counsel and Corporate Secretary
|
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024